Abstract: A suspension particle sensing apparatus includes a first flow channel, a suspension particle concentration sensor and a suspension particle filtering assembly. The first flow channel has a first entrance and a first exit. The suspension particle concentration sensor is disposed in the first flow channel, and is located between the first entrance and the first exit. The suspension particle filtering assembly is disposed at the first entrance, and includes a casing and a suspension particle filtering structure. The casing has a first opening and a second opening. The first opening is communicated with the first entrance of the first flow channel. The suspension particle filtering structure covers the second opening.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: Provided is a residual toxicant detection system and a residual toxicant detection method, the residual toxicant detection method including: allowing an aqueous solution containing a residual toxicant to flow into a detection portion including a cavity; providing at a side of the cavity a light containing a specific wavelength range to react with the residual toxicant; receiving the light that passes through the cavity on another side of the cavity, thereby generating a sensing signal; and calculating an amount of change in absorbance of the aqueous solution according to the sensing signal, wherein when the amount of change in absorbance is less than a threshold value, a detection count is accumulated, and when the accumulated detection count is greater than a predetermined value, a detection result is generated. Therefore, whether or not the residual toxicant on the object is cleaned can be determined easily and accurately.

Abstract: A process of producing an extinguishing agent includes dissolving 5 g to 90 g of diammonium hydrogen phosphate, 0.1 g to 60 g of urea, 1 g to 90 g of ammonium carbonate, 5 g to 90 of ammonium sulfate, and 20 g to 250 g of potassium carbonate in 400 ml to 550 ml of water at a temperature of 30° C. to 90° C. to form a first solution; mixing the first solution with 5 g to 500 g of surfactant to undergo a first reaction for forming a second solution; and mixing the second solution with 1000 ml of water to undergo a second reaction for forming an extinguishing agent.

Abstract: The present invention provides a compound having a structure of formula (I), a preparation method and use thereof, and a pharmaceutical composition containing the compound, wherein R is methyl, ethyl, propyl, vinyl or propenyl. The present invention also provides a crystalline form of the compound, a preparation method and use of the crystalline form, and a pharmaceutical composition comprising the crystalline form. The compounds having the structure of formula (I) of the present invention are present in a solid form, which not only can solve the problem of clopidogrel resistance, but also can solve the problem of severe hemorrhagic side effect and poor safety of some drugs, as well as the problem of poor stability of existing compounds. It can be developed into an ADP receptor antagonist antiplatelet agent with clear therapeutic effect, no resistance and better stability.

Abstract: Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: A collision control method and apparatus, and a storage medium are provided. The method includes obtaining a collision action to be performed by a first control object in a game client and entity information of the first control object. The entity information includes first entity information representing a skeleton of the first control object, and second entity information representing a group of colliders of the first control object excluding the skeleton and driven by the skeleton. The skeleton and the group of colliders are controlled to perform the collision action of the first control object with a second control object based on the entity information.

Abstract: Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: Provided herein are compounds of formula (I)-(VI): wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: A high frequency time-division multi-phase power converter includes a power source, a switching circuit, a first resonant tank, a coreless transformer, a second resonant tank, an output rectifier circuit, an output load circuit and a control circuit. The switching circuit includes a first half bridge circuit and a second half bridge circuit connected in parallel. The first resonant tank includes a first resonant inductor, a first resonant capacitor and a first magnetizing inductor. The coreless transformer includes a primary side coil and a secondary side coil. The second resonant tank includes a second resonant capacitor and a second resonant inductor. The control circuit controls the switching circuit to be switched between multiple switching states, and ON states in a switching cycle of the first upper bridge switch, the first lower bridge switch, the second upper bridge switch, and the second lower bridge switch are mutually exclusive.

Abstract: A blade pitch drive comprising a driver sprocket, a driven sprocket, a toothed belt trained between the driver sprocket and driven sprocket, the toothed belt having a free span between the driver sprocket and driven sprocket, the free span having an arcuate form when the free span is in a slack condition, the toothed belt having a second span between the driver sprocket and driven sprocket in a tight condition when the free span is in a slack condition, and the free span operable as the second span and the second span operable as the free span according to an operating direction of the drive.

Abstract: A suspension particle sensing apparatus includes a first flow channel, a suspension particle concentration sensor and a suspension particle filtering assembly. The first flow channel has a first entrance and a first exit. The suspension particle concentration sensor is disposed in the first flow channel, and is located between the first entrance and the first exit. The suspension particle filtering assembly is disposed at the first entrance, and includes a casing and a suspension particle filtering structure. The casing has a first opening and a second opening. The first opening is communicated with the first entrance of the first flow channel. The suspension particle filtering structure covers the second opening.

Abstract: Provided herein are compounds of formula (I)-(VI): wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: An interleaved LLC half-bridge series resonant converter having an integrated transformer includes a power supply, a magnetic core, a first converter, a second converter and an output load circuit. The magnetic core has first and second outer columns and a center column. The first converter includes a first switch circuit, a first resonant tank, a first transformer, and a first rectifier circuit. The first transformer is coupled to the first resonant tank and includes a first primary winding wound on the first outer column and a first secondary winding wound on the second outer column. The second converter includes a second switch circuit, a second resonant tank, a second transformer and a second rectifier circuit. The second transformer is coupled to the second resonant tank and includes a second primary winding wound on the first outer column and a second secondary winding wound on the second outer column.